Business and Organization - Liquidity and Financial Condition (Details) $ / shares in Units, $ in Thousands		3 Months Ended						9 Months Ended
	May 24, 2018 $ / shares	Sep. 30, 2019 USD ($) $ / shares	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Sep. 30, 2019 USD ($) $ / shares	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($) $ / shares	Jul. 02, 2018 $ / shares	Dec. 31, 2017 USD ($)
Business Acquisition [Line Items]
Net income (loss)		$ (7,204)	$ 11,743	$ (3,666)	$ (2,859)	$ (2,894)	$ (2,901)	$ 873	$ (8,654)
Cash used in operating activities								7,285	10,217
Cash and cash equivalents		6,768						6,768		$ 14,430
Working capital		15,000						15,000
Accumulated deficit		$ 188,207						$ 188,207		$ 189,080
Stock split, conversion ratio	0.2
Common stock, par value (in dollars per share) | $ / shares	$ 0.001	$ 0.001						$ 0.001		$ 0.001	$ 0.001
Stockholders equity		$ 10,741	$ 17,863	$ 6,003	$ 10,184	$ 9,368	$ 6,259	$ 10,741	$ 10,184	$ 9,557		$ 9,007
Castle Creek Pharmaceutical Holdings | Fibrocell Science, Inc.
Business Acquisition [Line Items]
Maximum amount of advance from CCP		3,000						3,000
Maximum amount of equity capital to be raised		$ 3,000						$ 3,000